Eli Lilly and Co LLY on Thursday issued a public warning about potential safety risks linked to compounded tirzepatide ...

WASHINGTON, March 12 (Reuters) - Compounded weight-loss drugs that contain vitamin B12 and the main ingredient in Eli Lilly's Zepbound could present health risks to consumers due to a previously ...

Combining tirzepatide with vitamin B12, a common additive in compounded versions of the drug, yields an impurity that could ...

She found plenty of options and settled on a cheaper, imitation version of the name-brand drugs for $177 a month that she could buy without going through insurance. “It’s absolutely odd,” she said of ...

A proposed bill in the Colorado General Assembly bill is aiming to regulate the ingredients used for transparency and safety.

The BPS is reviewing a petition from several professional organizations and seeking public comments on creating a new ...

Lilly said it notified the FDA of its findings and called for a nationwide recall of products containing both ingredients ...

This article first appeared on GuruFocus. Shares of Eli Lilly and Company (NYSE:LLY) slipped about 1% in early Thursday trading after the drugmaker cautioned about potential safety concerns tied to ...

Recently, there has been a lot of news around the use of peptides in health circles. The U.S. Department of Health and Human Services recently announced that bans on 14 ...

This article first appeared on GuruFocus. Shares of Hims & Hers Health (NYSE:HIMS) climbed about 5% on Thursday morning after the telehealth company said it entered a collaboration with Novo Nordisk ...

Wasn’t this GLP-1 compounding tussle supposed to be over by now? FDA has sent warning letters to 30 telehealth companies warning them about their continued sale of compounded GLP-1 drugs. The warning ...

近日，美国食品药品监督管理局（FDA）公布了一封对销售调配药品机构发出的警告信。该信基于FDA 2025年12月对该公司网站内容的审查，指出其网站提供的司美格鲁肽和替尔泊肽等调配药品存在宣传误导问题。下面对信中指出的问题进行分析： 该网站展示的调配 ...